Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong. (2019)
Attributed to:
Glasgow Molecular Pathology (GMP) Node
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0215279
PubMed Identifier: 30990840
Publication URI: http://europepmc.org/abstract/MED/30990840
Type: Journal Article/Review
Volume: 14
Parent Publication: PloS one
Issue: 4
ISSN: 1932-6203